Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity

Journal of Medicinal Chemistry

Volumn 54, Issue 19, 2011, Pages 6492-6500

  Rivera, Corban G ^a,b   Rosca, Elena V ^a   Pandey, Niranjan B ^a   Koskimaki, Jacob E ^a   Bader, Joel S ^a,b   Popel, Aleksander S ^a  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGEN TYPE 4; SP 2000; SP 2002; SP 2004; SP 2006; SP 2007; SP 2008; SP 2009; SP 2010; SP 2011; SP 2012; SP 2013; SP 2014; SP 2015; SP 2016; SP 2017; SP 2020; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ANGIOGENESIS INHIBITORS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE IV; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIGANDS; MODELS, MOLECULAR; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053915567     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200114f     Document Type: Article

References (39)

1. Folkman, J. Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 1971, 285, 1182-1186
2. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discovery 2007, 6, 273-286 (Pubitemid 46505878)
3. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 1997, 88, 277-285 (Pubitemid 28015876)
4. Kamphaus, G. D.; Colorado, P. C.; Panka, D. J.; Hopfer, H.; Ramchandran, R.; Torre, A.; Maeshima, Y.; Mier, J. W.; Sukhatme, V. P.; Kalluri, R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth J. Biol. Chem. 2000, 275, 1209
5. Nyberg, P.; Xie, L.; Sugimoto, H.; Colorado, P.; Sund, M.; Holthaus, K.; Sudhakar, A.; Salo, T.; Kalluri, R. Characterization of the anti-angiogenic properties of arresten, an [alpha] 1 [beta] 1 integrin-dependent collagen-derived tumor suppressor Exp. Cell Res. 2008, 314, 3292-3305
6. Maeshima, Y.; Sudhakar, A.; Lively, J. C.; Ueki, K.; Kharbanda, S.; Kahn, C. R.; Sonenberg, N.; Hynes, R. O.; Kalluri, R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis Science 2002, 295, 140
7. Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis Nat. Rev. Cancer 2003, 3, 422-433 (Pubitemid 37328846)
8. Mundel, T. M.; Kalluri, R. Type IV collagen-derived angiogenesis inhibitors Microvasc. Res. 2007, 74, 85-89 (Pubitemid 350051026)
9. Nyberg, P.; Xie, L.; Kalluri, R. Endogenous inhibitors of angiogenesis Cancer Res. 2005, 65, 3967
10. Karagiannis, E. D.; Popel, A. S. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 13775-13780
11. Karagiannis, E. D.; Popel, A. S. A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2 J. Biol. Chem. 2004, 279, 39105-39114 (Pubitemid 39296073)
12. Karagiannis, E. D.; Popel, A. S. Anti-angiogenic peptides identified in thrombospondin type I domains Biochem. Biophys. Res. Commun. 2007, 359, 63-69 (Pubitemid 46839218)
13. Karagiannis, E. D.; Popel, A. S. Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells Int. J. Biochem. Cell Biol. 2007, 39, 2314-2323 (Pubitemid 47484285)
14. Karagiannis, E. D.; Popel, A. S. Novel anti-angiogenic peptides derived from ELR-containing CXC chemokines J. Cell. Biochem. 2008, 104, 1356-1363 (Pubitemid 351961706)
15. Koskimaki, J. E.; Karagiannis, E. D.; Rosca, E. V.; Vesuna, F.; Winnard, P. T., Jr.; Raman, V.; Bhujwalla, Z. M.; Popel, A. S. Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts Neoplasia 2009, 11, 1285-1291
16. Koskimaki, J. E.; Karagiannis, E. D.; Tang, B. C.; Hammers, H.; Watkins, D. N.; Pili, R.; Popel, A. S. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model BMC Cancer 2010, 10, 29
17. Cano Mdel, V.; Karagiannis, E. D.; Soliman, M.; Bakir, B.; Zhuang, W.; Popel, A. S.; Gehlbach, P. L. A peptide derived from type 1 thrombospondin repeat-containing protein WISP-1 inhibits corneal and choroidal neovascularization Invest. Ophthalmol. Visual Sci. 2009, 50, 3840-3845
18. Rosca, E. V.; Koskimaki, J. E.; Rivera, C. G.; Pandey, N. B.; Tamiz, A. P.; Popel, A. S. Anti-angiogenic peptides for cancer therapeutics Curr. Pharm. Biotechnol. 2011, 12, 1101-1116
19. Dixon, S. L.; Smondyrev, A. M.; Knoll, E. H.; Rao, S. N.; Shaw, D. E.; Friesner, R. A. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results J. Comput.-Aided Mol. Des. 2006, 20, 647-671 (Pubitemid 46023928)
20. Schneidman-Duhovny, D.; Dror, O.; Inbar, Y.; Nussinov, R.; Wolfson, H. J. PharmaGist: a webserver for ligand-based pharmacophore detection Nucleic Acids Res. 2008, 36, W223-228
21. Güner, O. F., Ed. Pharmacophore Perception, Development, and Use in Drug Design; International Universit Line: La Jolla, CA, 1999.
22. Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudiniere, R. F. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures J. Med. Chem. 1999, 42, 3251-3264 (Pubitemid 29409714)
23. Blankley, C. Introduction: A Review of QSAR Methodology. In Quantitative Structure-Activity Relationships of Drugs; Topliss, J. G., Ed.; Academic Press: New York, 1983.
24. Dudek, A. Z.; Arodz, T.; Galvez, J. Computational methods in developing quantitative structure-activity relationships (QSAR): a review Comb. Chem. High Throughput Screening 2006, 9, 213-228
25. Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR: Fundamentals and Applications in Chemistry and Biology; American Chemical Society: Washington, DC, 1995.
26. Kubiny, H. Variable selection in QSAR studies. I. An evolutionary algorithm Quant. Struct.-Act. Relat. 1994, 13, 285-294
27. Lin, Z. H.; Long, H. X.; Bo, Z.; Wang, Y. Q.; Wu, Y. Z. New descriptors of amino acids and their application to peptide QSAR study Peptides 2008, 29, 1798-1805
28. Zhou, P.; Chen, X.; Shang, Z. Side-chain conformational space analysis (SCSA): a multi conformation-based QSAR approach for modeling and prediction of protein-peptide binding affinities J. Comput.-Aided Mol. Des. 2009, 23, 129-141
29. Doytchinova, I. A.; Blythe, M. J.; Flower, D. R. Additive method for the prediction of protein-peptide binding affinity. Application to the MHC class I molecule HLA-A* 0201 J. Proteome Res. 2002, 1, 263-272 (Pubitemid 36050256)
30. Finn, P.; Halperin, D.; Kavraki, L.; Latombe, J. C.; Motwani, R.; Shelton, C.; Venkatasubramanian, S. Geometric manipulation of flexible ligands Appl. Comput. Geom. Geom. Eng. 1996, 67-78 (Pubitemid 126140147)
31. Tibshirani, R. Regression shrinkage and selection via the Lasso J. R. Stat. Soc., Ser. B 1994, 58, 267-288
32. Hawkins, D. M.; Basak, S. C.; Mills, D. Assessing model fit by cross-validation J. Chem. Inf. Comput. Sci. 2003, 43, 579-586
33. Khoshnoodi, J.; Pedchenko, V.; Hudson, B. G. Mammalian collagen IV Microsc. Res. Tech. 2008, 71, 357-370 (Pubitemid 351620858)
34. Maeshima, Y.; Manfredi, M.; Reimer, C.; Holthaus, K. A.; Hopfer, H.; Chandamuri, B. R.; Kharbanda, S.; Kalluri, R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin J. Biol. Chem. 2001, 276, 15240-15248
35. Eikesdal, H. P.; Sugimoto, H.; Birrane, G.; Maeshima, Y.; Cooke, V. G.; Kieran, M.; Kalluri, R. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 15040
36. Arnaoutova, I.; George, J.; Kleinman, H. K.; Benton, G. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art Angiogenesis 2009, 12, 267-274
37. Tibshirani, R. Regression shrinkage and selection via the lasso J. R. Stat. Soc., Ser. B 1996, 58, 267-288
38. Grant, M.; Boyd, S. Graph implementations for nonsmooth convex programs Recent Adv. Learn. Control 2008, 95-110
39. Jones, D. T.; Taylor, W. R.; Thornton, J. M. The rapid generation of mutation data matrices from protein sequences Comput. Appl. Biosci. 1992, 8, 275